W81XWH-22-MBRP-TTDA: DoD Military Burn, Technology/Therapeutic Development Award
Closed
This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2022.
Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $4.4 million in total. Applications closed on October 11, 2022.
From the official notice on Grants.gov, last changed May 20, 2022. Checked November 7, 2026.
- Total funding$4.4 million
- Expected awards2
- Cost sharingNot required
- Funding typeCooperative Agreement, Grant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HT942525MBRPTTDA | May 1, 2025 | Closed September 8, 2025 | Closed |
| HT942524SMBRP | April 18, 2024 | Closed September 9, 2024 | Closed |
| HT9425-23-MBRP-TTDA | April 26, 2023 | Closed September 5, 2023 | Closed |
Key dates
| Posted | May 20, 2022 |
|---|---|
| Deadline | October 11, 2022 |
| Archived by Grants.gov | November 10, 2022 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (59% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The MBRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical application that address one or more of the critical gaps included in the FY22 MBRP TTDA Focus Areas. Products under development must be relevant to military application and address the needs of military Service Members, Veterans, and/or beneficiaries. The product(s) to be developed may be a tangible item such as a pharmacologic agent (including, but not limited to, drugs or biologics); or device-focused. Knowledge products may be considered, provided that the knowledge is applicable to a technology or therapeutic under development. (A “knowledge product” is a non-materiel product that addresses an identified need in one or more of the FY22 MBRP TTDA Focus Areas, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.) The Principal Investigator (PI) must provide a transition plan (including potential funding and resources; see Attachment 7: Transition Plan and Regulatory Strategy) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the MBRP award. At the time of pre-application submission the proposed product must be at a minimum technology readiness level (TRL) or knowledge readiness level (KRL) of 3 (Appendix 2). Proof-of-concept and prototype/preliminary version of the proposed product demonstrating the potential utility of the proposed product must be established at the time of pre-application submission. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature. This award mechanism is intended to facilitate progression of research that is supported by significant preliminary data but has not yet advanced to the level of clinical use.
Who has won Military Medical Research and Development grants before
From fiscal 2021 to 2025, Military Medical Research and Development (12.420) awarded $6.9 billion across 5,470 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 81 | $546 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 139 | $166 million |
| The Johns Hopkins University | Maryland | 157 | $153 million |
| The Regents of the University of California, San Francisco | California | 113 | $147 million |
| Duke University | North Carolina | 86 | $123 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is W81XWH-22-MBRP-TTDA still open?
No. It closed on October 11, 2022. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).
Who can apply for DoD Military Burn, Technology/Therapeutic Development Award?
Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.
What is the deadline for DoD Military Burn, Technology/Therapeutic Development Award?
Closed October 11, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $4.4 million in total across about 2 awards.
Who has won Military Medical Research and Development grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.